Temporary Change in PDL Status for Tetracyclines Drug Class, Effective January 11

Published on
January 12, 2022

HHSC is aware of a drug shortage for Vibramycin 25mg/5mL suspension in the Tetracyclines drug class because of the discontinuation of this product by Pfizer. We received reports of a shortage from MCOs and verified it through the U.S. Food and Drug Administration drug shortages website.

In response to the shortage of the preferred brand product Vibramycin 25mg/5mL suspension, national drug code (NDC) 0069-0971-95, HHSC temporarily removed the non-preferred status from the generic product, doxycycline 25mg/5mL suspension on the preferred drug list (PDL). HHSC removed the non-preferred status of the following drugs, effective January 11, 2022.

NDC Drug Name
62135-0417-46 DOXYCYCLINE 25 MG/5 ML SUSP
68180-0657-01 DOXYCYCLINE 25 MG/5 ML SUSP
69097-0228-43 DOXYCYCLINE 25 MG/5 ML SUSP

These changes will allow providers to prescribe the generic doxycycline suspension without requiring a PDL prior authorization and continue accessing necessary medication for clients. This is a temporary change until the preferred products are sufficiently available in the market. HHSC will provide further announcements regarding future PDL status changes for these NDCs.